These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30787172)

  • 21. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
    Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
    Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
    Lin YC; Liu CY; Kannagi R; Yang RB
    Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects.
    Kamli H; Owens EP; Vesey DA; Prasanna R; Li L; Gobe GC; Morais C
    Biochem Biophys Res Commun; 2022 Jan; 586():42-48. PubMed ID: 34826699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism.
    Baek YY; Lee DK; Kim J; Kim JH; Park W; Kim T; Han S; Jeoung D; You JC; Lee H; Won MH; Ha KS; Kwon YG; Kim YM
    Oncotarget; 2017 Feb; 8(7):11763-11777. PubMed ID: 28052029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Orai1 and transient receptor potential channels as novel molecular targets to impair tumor neovascularization in renal cell carcinoma and other malignancies.
    Moccia F; Dragoni S; Poletto V; Rosti V; Tanzi F; Ganini C; Porta C
    Anticancer Agents Med Chem; 2014 Feb; 14(2):296-312. PubMed ID: 23869775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
    Rini BI
    Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
    Ellis L; Shah P; Hammers H; Lehet K; Sotomayor P; Azabdaftari G; Seshadri M; Pili R
    Mol Cancer Ther; 2012 Feb; 11(2):383-92. PubMed ID: 22084164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sphingosine-1-phosphate-induced Flk-1 transactivation stimulates mouse embryonic stem cell proliferation through S1P1/S1P3-dependent β-arrestin/c-Src pathways.
    Ryu JM; Baek YB; Shin MS; Park JH; Park SH; Lee JH; Han HJ
    Stem Cell Res; 2014 Jan; 12(1):69-85. PubMed ID: 24145189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The role of angiogenesis in renal carcinoma].
    Bussolati B; Satolli MA; Camussi G
    G Ital Nefrol; 2008; 25(3):297-305. PubMed ID: 18473301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity.
    Eikesdal HP; Sugimoto H; Birrane G; Maeshima Y; Cooke VG; Kieran M; Kalluri R
    Proc Natl Acad Sci U S A; 2008 Sep; 105(39):15040-5. PubMed ID: 18818312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.
    LaMontagne K; Littlewood-Evans A; Schnell C; O'Reilly T; Wyder L; Sanchez T; Probst B; Butler J; Wood A; Liau G; Billy E; Theuer A; Hla T; Wood J
    Cancer Res; 2006 Jan; 66(1):221-31. PubMed ID: 16397235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sphingosine kinase 1/sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 pathway: A novel target of geniposide to inhibit angiogenesis.
    Sun M; Deng R; Wang Y; Wu H; Zhang Z; Bu Y; Zhang H
    Life Sci; 2020 Sep; 256():117988. PubMed ID: 32569777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.
    Inglis DJ; Lavranos TC; Beaumont DM; Leske AF; Brown CK; Hall AJ; Kremmidiotis G
    Cancer Biol Ther; 2014; 15(11):1552-60. PubMed ID: 25482941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyperoxia-induced S1P
    Sudhadevi T; Jafri A; Ha AW; Basa P; Thomas JM; Fu P; Wary K; Mehta D; Natarajan V; Harijith A
    Cell Biochem Biophys; 2021 Sep; 79(3):561-573. PubMed ID: 34176100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
    Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
    Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sphingosine-1-phosphate promotes osteogenesis by stimulating osteoblast growth and neovascularization in a vascular endothelial growth factor-dependent manner.
    Wille A; Weske S; von Wnuck Lipinski K; Wollnitzke P; Schröder NH; Thomas N; Nowak MK; Deister-Jonas J; Behr B; Keul P; Levkau B
    J Bone Miner Res; 2024 Apr; 39(3):357-372. PubMed ID: 38477738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy.
    Saylor PJ; Escudier B; Michaelson MD
    Clin Genitourin Cancer; 2012 Jun; 10(2):77-83. PubMed ID: 22382009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endothelial S1P
    Nitzsche A; Poittevin M; Benarab A; Bonnin P; Faraco G; Uchida H; Favre J; Garcia-Bonilla L; Garcia MCL; Léger PL; Thérond P; Mathivet T; Autret G; Baudrie V; Couty L; Kono M; Chevallier A; Niazi H; Tharaux PL; Chun J; Schwab SR; Eichmann A; Tavitian B; Proia RL; Charriaut-Marlangue C; Sanchez T; Kubis N; Henrion D; Iadecola C; Hla T; Camerer E
    Circ Res; 2021 Feb; 128(3):363-382. PubMed ID: 33301355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis.
    Kim DG; Jin Y; Jin J; Yang H; Joo KM; Lee WS; Shim SR; Kim SW; Yoo J; Lee SH; Yoo JS; Nam DH
    MAbs; 2015; 7(6):1195-204. PubMed ID: 26325365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.